Exelixis
EXEL
#1685
Rank
HK$79.14 B
Marketcap
HK$277.15
Share price
2.24%
Change (1 day)
63.98%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : HK$17.70 Billion

According to Exelixis's latest financial reports the company has HK$17.70 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$HK$17.68 B-9.06%
2022-12-31$HK$19.44 B12.79%
2021-12-31$HK$17.23 B18.33%
2020-12-31$HK$14.56 B10.94%
2019-12-31$HK$13.13 B30.24%
2018-12-31$HK$10.08 B352.84%
2017-12-31$HK$2.22 B221.44%
2016-12-31$HK$0.69 B-163.46%
2015-12-31$-HK$1.1 Billion22.53%
2014-12-31$-HK$0.9 Billion-273.41%
2013-12-31$HK$0.51 B-77.65%
2012-12-31$HK$2.29 B226.41%
2011-12-31$HK$0.70 B-139.62%
2010-12-31$-HK$1.78 Billion39.97%
2009-12-31$-HK$1.27 Billion192%
2008-12-31$-HK$0.44 Billion-165.21%
2007-12-31$HK$0.66 B-5.39%
2006-12-31$HK$0.70 B58.64%
2005-12-31$HK$0.44 B12.81%
2004-12-31$HK$0.39 B-68.54%
2003-12-31$HK$1.25 B-8.76%
2002-12-31$HK$1.37 B-25.83%
2001-12-31$HK$1.84 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
HK$140.12 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$609.03 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
HK$346.81 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$133.86 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$58.58 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$546.04 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$720.38 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$5.41 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.22 B-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA